Table 2. Follow up treatment for patients with localized progression after targeted therapy.

Driver gene types	Setting	Recommending
EGFR mutation	First-line osimertinib treatment	Osimertinib plus adjuvant local therapy
	First-line treatment with erlotinib, afatinib, and gefitinib (T790M−)	Original EGFR-TKI plus adjuvant local therapy; osimertinib is preferred for patients with brain metastases or meningeal invasion
	First-line treatment with erlotinib, afatinib, gefitinib (T790M+)	Osimertinib plus adjuvant local therapy
ALK fusion	First-line crizotinib treatment	Alectinib, ceritinib, brigatinib, lorlatinib, or ensartinib plus adjuvant local therapy
	First-line treatment with alectinib, ceritinib, brigatinib, lorlatinib	Original ALK-TKI plus adjuvant local therapy
ROS1 fusion	First-line treatment with crizotinib, ceritinib, entrectinib	Original ALK-TKI or lorlatinib, plus adjuvant local

ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; ROS1, ROS proto-oncogene 1, receptor tyrosine kinase; TKI, tyrosine kinase inhibitor.